President Trump has returned to the White House following his release from the hospital. Eurasia U.S. Analyst Jeff Wright joins the On the Move panel to discuss.
President Trump has returned to the White House following his release from the hospital. Eurasia U.S. Analyst Jeff Wright joins the On the Move panel to discuss.
The fungi are rich in a 'unique and potent' antioxidant. So it's well worth adding some to your risotto, omelette or pasta.
A $2.5 million forgivable loan program for Fayette County small businesses hobbled by the pandemic will likely be available in coming weeks.
New York, New York--(Newsfile Corp. - April 22, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Romeo Power, Inc. (NYSE: RMO) alleging that the Company violated federal securities laws.Class Period: October 5, 2020 and March 30, 2021Lead Plaintiff Deadline: June 15, 2021Learn more about your recoverable losses in RMO:http://www.kleinstocklaw.com/pslra-1/romeo-power-inc-loss-submission-form?id=15025&from=5The filed complaint alleges that Romeo Power, Inc. made materially false and/or misleading statements ...
Britain's biggest carmaker to suspend output at two factories because of global semiconductor shortage.
The new Freeform teen thriller Cruel Summer is making a big impression with its first few episodes, but how long will its buzzy first season last? If you're already hooked on the show's ongoing mysteries, there's good news: you've got a couple more months to keep theorizing until the season finale!
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria.
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ: HTHT and HKEX: 1179) (“Huazhu”, “we” or “our”), a world-leading hotel group, today announced preliminary results for hotel operations in the first quarter (“Q1 2021”) ended March 31, 2021. COVID-19 update Due to COVID-19 resurgence in Shanghai, Beijing and Hebei Province and the “stay local” guidance prior to the Chinese New Year holiday (CNY), RevPAR in January and February 2021 recovered to 74% and 56% of 2019 respectively. Our hotel openings were also negatively impacted by the resurgence of COVID-19 during the first quarter. However, our performance started to recover steadily again post the CNY holiday. Particularly, after the National People’s Congress and the Chinese People’s Political Consultative Conference during the first week of March, the Chinese government further eased travel restrictions which were in effect from March 16, 2021. After that, we saw strong recovery in hotel demand in the Beijing area, followed by other major tier 1 cities. Our RevPAR in March 2021 recovered to 95% of 2019, mainly driven by the strong recovery of business demand. Heading into April, the recovery trend continued. Our RevPAR during the Tomb Sweeping holiday recovered to 96% of same period of 2019, which demonstrated the strong recovery of leisure demand. Steigenberger Hotels AG and its subsidiaries (“DH”) suffered from the several resurgences of COVID-19 pandemic in European countries. The lock down period there has been extended several times, and most likely to further extend to the end of May, 2021. European countries began their vaccination process in December 2020. However, due to the uncertainty of the completion of the vaccination process, and consequently the timing of business recovery, we are taking further cost reduction and cash flow measures, such as negotiating with landlords to reduce our rental costs, reducing or eliminating discretionary corporate spending and capital expenditures, etc. However, the extension of lockdown impacts should be partially offset by extension of the scope and duration of European government subsidy programs.Operating Results: Legacy-Huazhu(1) Number of hotels Number of rooms Opened in Q1 2021Closed (2)in Q1 2021Net added in Q1 2021As of March 31, 2021 (3) As of March 31, 2021 Leased and owned hotels2(19)(17)664 89,901Manachised and franchised hotels207(98)109 6,097 548,718Total209(117)92 6,761 638,619 (1) Legacy-Huazhu refers to Huazhu and its subsidiaries, excluding DH.(2) The reasons for hotel closures mainly include non-compliance with our brand standards, operating losses, and property-related issues. In Q1 2021, we temporarily closed 16 hotels for brand upgrade and business model change purposes.(3) As of March 31, 2021, 43 hotels were requisitioned by governmental authorities. As of March 31, 2021 Number of hotels Unopened hotels in pipeline Economy hotels4,3831,269Leased and owned hotels4225Manachised and franchised hotels3,9611,264Midscale and upscale hotels2,3781,339Leased and owned hotels24214Manachised and franchised hotels2,1361,325Total6,7612,608 Operational hotels excluding hotels under requisition For the quarter ended March 31,December 31,March 31,yoy 202020202021changeAverage daily room rate (in RMB) Leased and owned hotels21127224315.6%Manachised and franchised hotels18422420310.2%Blended18923120910.6%Occupancy rate (as a percentage) Leased and owned hotels43.8%79.6%64.0%20.2 p.p.Manachised and franchised hotels47.4%80.8%66.6%19.2 p.p.Blended46.7%80.6%66.2%19.5 p.p.RevPAR (in RMB) Leased and owned hotels9221715668.9%Manachised and franchised hotels8718113554.9%Blended8818613856.7% For the quarter ended March 31,March 31,yoy 20192021changeAverage daily room rate (in RMB) Leased and owned hotels258243-5.6%Manachised and franchised hotels211203-3.9%Blended221209-5.6%Occupancy rate (as a percentage) Leased and owned hotels83.6%64.0%-19.6p.p.Manachised and franchised hotels79.8%66.6%-13.3p.p.Blended80.6%66.2%-14.4p.p.RevPAR (in RMB) Leased and owned hotels216156-27.8%Manachised and franchised hotels169135-19.9%Blended178138-22.5% Same-hotel operational data by class Mature hotels in operation for more than 18 months (excluding hotels under requisition) Number of hotelsSame-hotel RevPARSame-hotel ADRSame-hotel Occupancy As ofMarch 31,For the quarter yoyFor the quarter yoyFor the quarter yoy ended March 31,changeended March 31,changeended March 31,change 2020202120202021 20202021 20202021(p.p.)Economy hotels2,8322,8328011342.1%1531604.9%52.0%70.5%18.4Leased and owned hotels4174177912050.8%1641757.3%48.5%68.2%19.7Manachised and franchised hotels2,4152,4158011140.0%1501574.4%53.0%71.0%18.1Midscale and upscale hotels1,3771,37711117658.2%2602787.0%42.7%63.1%20.4Leased and owned hotels19819811319168.6%2973269.5%38.1%58.7%20.6Manachised and franchised hotels1,1791,17911017255.6%2512686.6%44.0%64.2%20.2Total4,2094,2099213850.2%1902047.6%48.4%67.5%19.2 Number of hotelsSame-hotel RevPARSame-hotel ADRSame-hotel Occupancy As ofMarch 31,For the quarter yoyFor the quarter yoyFor the quarter yoy ended March 31,changeended March 31,changeended March 31,change 2019202120192021 20192021 20192021(p.p.)Economy hotels2,2902,290158110-30.0%181158-12.7%87.1%69.8%-17.3Leased and owned hotels396396175117-33.1%199173-13.1%88.1%67.9%-20.2Manachised and franchised hotels1,8941,894153109-29.1%176154-12.4%86.9%70.4%-16.5Midscale and upscale hotels842842248174-30.0%321279-13.0%77.2%62.2%-15.0Leased and owned hotels173173302189-37.4%381319-16.4%79.1%59.2%-19.9Manachised and franchised hotels669669229168-26.5%299266-11.0%76.5%63.2%-13.3Total3,1323,132187131-29.9%224195-12.6%83.9%67.3%-16.6 Operating Results: Legacy-DH(4) Number of hotels Number of rooms Unopened hotels in pipeline Opened in Q1 2021Closedin Q1 2021Net added in Q1 2021As of March 31, 2021(5) As of March 31, 2021 As ofMarch 31, 2021 Leased hotels1- 1 73 13,527 27Manachised and franchised hotels-(1)(1)47 10,366 14Total 1 (1) - 120 23,893 41 (4) Legacy-DH refers to DH. (5) As of March 31, 2021, a total of 20 DH brand hotels were temporarily closed due to COVID-19. For the quarter ended March 31,December 31,March 31,yoy 202020202021changeAverage daily room rate (in EUR) Leased hotels96.878.477.9-19.6%Manachised and franchised hotels79.573.359.0-25.8%Blended89.376.368.5-23.3%Occupancy rate (as a percentage) Leased hotels52.6%20.9%14.6%-38.0p.p.Managed and franchised hotels50.4%25.4%26.5%-24.0p.p.Blended51.7%22.5%18.8%-32.8p.p.RevPAR (in EUR) Leased hotels51.016.411.4-77.7%Managed and franchised hotels40.118.615.6-61.0%Blended126.96.36.199-72.1% Hotel Portfolio by Brand As of March 31, 2021 HotelsRoomsUnopened hotels in operationin pipelineEconomy hotels4,397363,4941,280HanTing Hotel2,767255,385659Hi Inn43625,22899Elan Hotel(6)97259,319468Ibis Hotel20821,90143Zleep Hotels141,66111Midscale and upscale hotels2,484299,0181,369Ibis Styles Hotel708,11926Starway Hotel45338,110272JI Hotel1,137139,943577Orange Hotel34538,537181Crystal Orange Hotel12116,24069Manxin Hotel636,15554Madison Hotel253,85043Mercure Hotel10817,84664Novotel Hotel123,38714Joya Hotel101,8420Blossom House271,27226Grand Mercure Hotel71,4856Steigenberger Hotels & Resorts4911,5749IntercityHotel(7)457,93121MAXX by Steigenberger(8)57774Jaz in the City24242Other partner hotels51,5261Total6,881662,5122,649(6) As of March 31, 2021, 9 Ni Hao Hotels were included in the operational hotel total for Elan Hotels and 96 Ni Hao hotels were included in the pipeline total for Elan Hotels.(7) As of March 31, 2021, 4 pipeline hotels of IntercityHotel were in China.(8) As of March 31, 2021, 3 pipeline hotels of MAXX by Steigenberger were in China. About Huazhu Group LimitedOriginated in China, Huazhu Group Limited is a world-leading hotel group. As of March 31, 2021, Huazhu operated 6,881 hotels with 662,512 rooms in operation in 16 countries. Huazhu’s brands include Hi Inn, Elan Hotel, HanTing Hotel, JI Hotel, Starway Hotel, Orange Hotel, Crystal Orange Hotel, Manxin Hotel, Madison Hotel, Joya Hotel, Blossom House, and Ni Hao Hotel. Upon the completion of the acquisition of DH on January 2, 2020, Huazhu added five brands to its portfolio, including Steigenberger Hotels & Resorts, MAXX by Steigenberger, Jaz in the City, IntercityHotel and Zleep Hotels. In addition, Huazhu also has the rights as master franchisee for Mercure, Ibis and Ibis Styles, and co-development rights for Grand Mercure and Novotel, in the pan-China region. Huazhu’s business includes leased and owned, manachised and franchised models. Under the lease and ownership model, Huazhu directly operates hotels typically located on leased or owned properties. Under the manachise model, Huazhu manages manachised hotels through the on-site hotel managers that Huazhu appoints, and Huazhu collects fees from franchisees. Under the franchise model, Huazhu provides training, reservations and support services to the franchised hotels, and collects fees from franchisees but does not appoint on-site hotel managers. Huazhu applies a consistent standard and platform across all of its hotels. As of March 31, 2021, Huazhu operates 16 percent of its hotel rooms under lease and ownership model, and 84 percent under manachise and franchise models. For more information, please visit Huazhu’s website: http://ir.huazhu.com. Safe Harbor Statement Under the U.S. Private Securities Litigation Reform Act of 1995: The information in this release contains forward-looking statements which involve risks and uncertainties. Such factors and risks include our anticipated growth strategies; our future results of operations and financial condition; economic conditions; the regulatory environment; our ability to attract and retain customers and leverage our brands; trends and competition in the lodging industry; the expected growth of demand for lodging; and other factors and risks detailed in our filings with the U.S. Securities and Exchange Commission. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as “may,” “should,” “will,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “forecast,” “project” or “continue,” the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Huazhu undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Contact InformationHuazhu Investor RelationsTel: 86 (21) 6195 9561Email: email@example.com://ir.huazhu.com
Yesterday marked Her Majesty's first birthday without her husband
INTRODUCTION Cancer is one of the leading causes of death worldwide, accounting for an estimated 0. 6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years.New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Immunocytokines Market by Indication, Route of Administration, and Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06064689/?utm_source=GNW It is a well-known fact that the conventional treatment options, such as chemotherapy, radiation therapy, and surgery, demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of traditional chemotherapy and radiation therapy, have been demonstrated to have detrimental effects on patients’ quality of life. Amongst the emerging class of targeted anti-cancer therapies, immunotherapy has emerged as a versatile option, having demonstrated the capability to selectively target and eliminate tumor cells. As a result, such products have favorable side effects profiles. For instance, immune check point inhibitors (such as atezolizumab, nivolumab, and pembrolizumab) have been demonstrated to offer long term clinical benefits to patients suffering from metastatic tumors. Similarly, other immunotherapies, such as dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells have shown promising results in eradicating primary and metastasized cancer cells. However, these therapies have been associated with severe and often life-threatening side effects, such as cytokine storm. Moreover, for T cell therapies, mispairing of endogenous and transfected TCR ? and ? chains have been demonstrated to have detrimental biological effects.Traditionally, cytokines have been investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents. However, the systemic administration of such potent, biologically-active molecules has been shown to be associated with a wide range of dose-dependent side effects and unfavorable pharmacokinetic properties, which, in a way, hinders dose escalation to therapeutically beneficial levels. To overcome the treatment-limiting toxicities of cytokines, researchers are now focusing on immunocytokines. Immunocytokines are fusion proteins, featuring the target specificity of antibodies and the immunological response mediating capabilities of specific cytokines. These engineered pharmacologically-active molecules have, so far, demonstrated better efficacy and reduced toxicity compared to conventional cytokine-based therapies. As a result, immunocytokines are now being investigated for the treatment of a wide array of target indications, including cancers, autoimmune disorders, and certain chronic inflammatory diseases. It is also worth highlighting that this upcoming class of molecules has been demonstrated to work in synergy with certain other established therapeutics, including small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines. Driven by encouraging clinical trial results, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.SCOPE OF THE REPORTThe “Immunocytokines Market, 2020-2030” report features an extensive study of the current and future potential of immunocytokines being developed for the treatment of rheumatoid arthritis and various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes: A detailed review of the current market landscape of immunocytokines, providing information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-?, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the report presents the details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters. Tabulated profiles of prominent immunocytokine developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook. An analysis of recent developments in the field of immunocytokines. It includes partnerships inked by various stakeholders in this domain, during the period between January 2016 and October 2020, covering clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others. In addition, the report features an analysis of the investments made, including debt funding, equity, venture capital financing, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing immunocytokines. An in-depth analysis of completed, ongoing, and planned clinical studies of various immunocytokines, based on various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions. A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contribution (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as disease prevalence, anticipated adoption of immunocytokines, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: Stephen Gillies, President and CEO, Provenance Biopharmaceuticals Patrik Kehler, Senior Director Scientific and Business Development, GlycotopeAll actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts’ viewsWhile the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.KEY QUESTIONS ANSWERED Who are the leading players engaged in the development of immunocytokines? Which cancer indications can be treated with immunocytokines? Which partnership models are commonly adopted by stakeholders engaged in this domain? What are the investment trends in this industry? Which are the most active clinical trial centers? Who are the key opinion leaders that can help you drive your development efforts? How is the current and future market opportunity likely to be distributed across key market segments?CHAPTER OUTLINESChapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for immunocytokines and its likely evolution in the short-mid-term and long term.Chapter 3 provides an introduction to immunocytokines, featuring brief descriptions of cytokines that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of engineered cytokines. The chapter lays emphasis on the advantages of engineered cytokines, including immunocytokines, and provides details on the strategies for the development of such therapies. It also features a brief discussion on the opportunities and the likely future trends in this field.Chapter 4 provides information on over 75 immunocytokines that are currently under development for the treatment of rheumatoid arthritis and various cancer indications. It features a detailed analysis of pipeline molecules, based on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-?, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the chapter includes details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.Chapter 5 provides tabulated profiles of the companies that are engaged in the development of more than three immunocytokines. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.Chapter 6 provides an insightful analysis of recent developments in this domain. It features list of partnerships that have been inked by stakeholders in this domain, during the period between January 2016 and October 2020, and a brief description of partnership models (such as clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others). In addition, the report features an analysis of the investments made at various stages of development in companies focused on developing immunocytokines.Chapter 7 provides a detailed analysis of completed, ongoing, and planned clinical studies of various immunocytokines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.Chapter 8 provides an analysis of KOLs in the field of immunocytokines. It features a comprehensive list of principal investigators of different clinical trials, along with information on the affiliated research institutes. The chapter features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters, such as number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).Chapter 9 features an insightful market forecast analysis, highlighting the likely growth of immunocytokines market, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.Chapter 10 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Stephen Gillies (President and CEO, Provenance Biopharmaceuticals) and Patrik Kehler (Senior Director Scientific and Business Development, Glycotope).Chapter 11 summarizes the entire report. It presents the key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of the immunocytokines market.Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.Chapter 13 is an appendix, which contains a list of companies and organizations mentioned in this report.Read the full report: https://www.reportlinker.com/p06064689/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
New York, New York--(Newsfile Corp. - April 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BELLUS Health Inc. ("BELLUS Health") (NASDAQ: BLU) between September 5, 2019 and July 5, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To ...
LONDON — British music's leading prize night next month will feature an audience of 4,000 people, in what will be the first major indoor music event in the country to welcome back a live audience since the coronavirus pandemic erupted more than a year ago. The Brit Awards said Thursday that the May 11 event at London's 02 Arena has been picked to be part of the government’s easing of coronavirus restrictions following a sharp drop in new cases in the U.K. As part of the government's live events pilot program, audience members attending the ceremony won't have to socially distance or even wear face coverings once seated. Instead, they will need to provide proof of a negative coronavirus test result to enter the venue and be required to provide details to test and trace authorities as well as follow the guidance while travelling to and from the venue. Organizers said they are giving away 2,500 tickets to essential workers from the Greater London area to mark their work through “the difficult times” of the pandemic. “This has been a long tough year for everyone and I’m delighted the night will honour the key worker heroes who have cared for us so well during that time and continue to do so,” said singer/songwriter Dua Lipa, who is set to perform at the event. “They are quite simply an inspiration.” Though the U.K. has Europe's highest coronavirus death toll of more than 127,000, restrictions are slowly being eased following a sharp fall in new infections in the wake of a stringent lockdown and the rapid rollout of vaccines. As part of that easing of restrictions, which has already seen schools reopen and pubs allowed to serve food and drink in outdoor settings, the government is trialing ways to allow audiences back at indoor cultural events. The Events Research Programme is looking at how venues can restart large events and welcome crowds back safely this summer, by which time the government hopes many of the curbs that have been in place since last March will have been ditched. Culture Secretary Oliver Dowden said this year's awards will be particularly special as they will “reunite live audiences with the best of British talent for the first time in a year, while providing a vital opportunity to see how we can get large crowds back safely as soon as possible.” In addition to Dua Lipa, organizers said Griff, Arlo Parks and Headie One are among the artists scheduled to perform during the ceremony, which will be hosted by comedian Jack Whitehall. “Not only will we be celebrating the brilliant music and artists that have helped us through the pandemic, but we hope it will provide a path for the return of live music that fans and artists have so sorely missed,” said Geoff Taylor, the chief executive of the British Phonographic Industry and of the Brit Awards. “We’re buzzing about the show and working closely with government," he added. The announcement comes after the Grammy Awards hosted a 2021 edition in Los Angeles, which saw nominees and performers, including Harry Styles and Beyonce, attend in person but without a live audience. ___ Follow AP’s pandemic coverage at: https://apnews.com/hub/coronavirus-pandemic https://apnews.com/hub/coronavirus-vaccine https://apnews.com/UnderstandingtheOutbreak Pan Pylas, The Associated Press
St. Anthony’s School has shared the news that two of its students, Madelyn Thomson and Joseph Weerasinghe have placed in the top 10 in the first round of the Your Voice is Power competition. The competition, which began in February, was presented by Amazon, Georgia Tech, and Pharrell Williams’ philanthropic organization, Yellow, to demonstrate how computer science, music, and entrepreneurship can advance equity. St. Anthony’s music teacher, Turner Ruetz, introduced the competition to his students. He said the songs created by Thomson and Weerasinghe were awarded top honours in music, coding and message by a panel of industry professionals. Each student won $200, a conversation with Pharrell Williams’ sound engineer and the opportunity to compete for the grand prize of $5,000 and a conversation with Pharrell Williams. “This competition is about making music, learning how to code and promoting equity,” said Ruetz. “Your Voice is Power is a North American wide competition that started in February (Black History Month). Teachers (could) sign up for Zoom sessions to learn about the program (discussions around equity, how to code using the program Earsketch and song structure). Then teachers introduce the competition to students in their classroom, which is to ultimately create a remix of Pharrell William's song Entrepreneur, while embedding messages of equity and fair treatment into their code.” Ruetz said his students have been working on their remixes for weeks. Each week he would introduce a new function within the coding program. They would then analyze and discuss the lyrics of Entrepreneur and resume work on their remixes. The finished product should be 30 seconds to three minutes long, and will be judged based on the quality of music, code and the messaging, by a panel of industry professionals from Amazon and Yellow. Thomson and Weerasinghe are two of less than two dozen students from Canada and the United States that are competing for top honours. There are five grand prizes of a $5,000 scholarship or a grant to start a business. The top 10 finalists will receive a $200 Amazon gift certificate and Yellow merchandise. Judges will provide feedback and suggestions for adjustments to their songs before the round two deadline of June 4. Finalists will be announced in mid-June and the grand prize winner will be named at the end of June. Tammy Lindsay Schneider, Local Journalism Initiative Reporter, Kincardine Independent
U.S. stock index futures were subdued on Thursday as investors assessed earnings from companies, including Southwest Airlines and AT&T, while awaiting weekly jobless claims data for clues on the pace of recovery in the U.S. labor market. Shares of AT&T Inc gained 1% in premarket trading after the company's wireless subscriber additions trounced analysts' estimates. Southwest Airlines Co posted a smaller-than-expected quarterly adjusted loss and forecast lower cash burn in the second quarter.
Dublin, April 22, 2021 (GLOBE NEWSWIRE) -- The "Ultrasonic Testing Market with COVID-19 Impact by Type (Time-of Flight Diffraction, Immersion Testing), Equipment (Flaw Detectors, Imaging System, and Bond Testers), Service, Vertical, and Geography - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global ultrasonic testing market size is estimated to grow from USD 3.0 Billion in 2021 to USD 4.2 Billion by 2026, at a CAGR of 7.1%. Stringent government regulations regarding public safety & product quality and continuous advances in electronics, automation, and robotics are a few major factors driving the ultrasonic testing market growth. The high adoption of IoT devices and the rising need to assess the health of aging assets are the other factors that propel the development of the ultrasonic testing market. Based on type, the market for the phased array type to witness a high CAGR during the forecast period. The phased array testing type is expected to multiply during the forecast period from 2021 to 2026. This type is used to measure or identify the subsurface cracks & seams, flaws, crack depth, coating thickness, and permeability. Phased array type reduces the use of multiple elements to steer, focus, and scan beams with a single transducer assembly. It optimizes defect detection and minimizes inspection time. It is used widely in power generation, construction and manufacturing verticals and service environments that inspect safety or quality-related issues. The phased array type is used to check surface-breaking cracks on metals and inspect discontinuities in metal tubes. Training services to grow at the highest CAGR during the forecast period. Training services are likely to continue to gain the second-largest market share in the coming years since training NDT technicians to keep them updated with new technological trends and make them aware of the customers' changing demands is equally essential. The market for training services is expected to grow at the highest CAGR during the forecast period. APAC to be the fastest-growing market for ultrasonic testing activities The Asia Pacific is likely to be the fastest-growing region in the ultrasonic testing market due to the rapid infrastructural development and automation adoption in manufacturing industries in countries such as India and China. The Make in India campaign promotion by the government and the development in the Smart Cities project provide lucrative opportunities for the players in the ultrasonic testing market in India. The market in India is expected to grow at the highest CAGR during the forecast period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights4.1 Lucrative Opportunities in Ultrasonic Testing Market4.2 Ultrasonic Testing Market, by Service4.3 Ultrasonic Testing Market, by Equipment and Region4.4 Ultrasonic Testing Market, by Type4.5 Ultrasonic Testing Market, by Region4.6 Market Growth Rate of Major Countries, 2021-2026 5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers188.8.131.52 Development of Portable Phased Array Ultrasonic Testing Equipment184.108.40.206 Need for Reliable Non-Destructive Testing Technique for Fiberglass and Carbon Fiber Composites in Manufacturing220.127.116.11 Growth in Ultrasonic Testing Market Services18.104.22.168 Government Mandates Regarding Employee Safety and Stringent Quality Control Requirements22.214.171.124 Maintenance Needs of Aging Infrastructure5.2.2 Restraints126.96.36.199 Limitations of Manual Ultrasonic Testing in Detecting Early Stages of Damage188.8.131.52 High Cost of Automated Ultrasonic Testing Equipment5.2.3 Opportunities184.108.40.206 Growing Infrastructure Development in Emerging Economies220.127.116.11 Opportunities in Power Generation Sector5.2.4 Challenges18.104.22.168 Decreasing Oil and Gas Prices22.214.171.124 Lack of Skilled Technicians5.3 Average Selling Price Analysis5.4 Leading Associations, Regulations, and Standards5.4.1 The American Society for Non-Destructive Testing5.4.2 The British Institute of Non-Destructive Testing5.4.3 Astm International5.5 Tariffs5.5.1 Negative Impact of Tariffs on Ultrasonic Testing Market5.5.2 Positive Impact of Tariffs on Ultrasonic Testing Market5.6 Case Studies5.6.1 Evaluation of Cracks in Petroleum Pipeline5.6.2 Image Data Processing in Automated Ultrasonic Testing5.7 Porter's Five Forces Analysis5.7.1 Threat of New Entrants5.7.2 Threat of Substitutes5.7.3 Bargaining Power of Suppliers5.7.4 Bargaining Power of Buyers5.7.5 Intensity of Competitive Rivalry 6 Industry Trends6.1 Introduction6.2 Value Chain Analysis6.2.1 Core Industry Segments126.96.36.199 Raw Material Providers188.8.131.52 Component Manufacturers184.108.40.206 Assemblers220.127.116.11 Sales and Distribution and Equipment Services18.104.22.168 End-Use Applications6.3 Key Industry Trends in Ultrasonic Testing Market6.4 Patent Analysis6.5 Ecosystem/Market Map6.6 Trade Analysis6.6.1 Import Scenario6.6.2 Exports Scenario6.7 Technology Analysis6.7.1 Key Technologies22.214.171.124 Electromagnetic Acoustic Transducer (Emat) Technique126.96.36.199 Long-Range Ultrasonic Technique (LRUT)6.7.2 Complementary Technologies188.8.131.52 Dynamic Thermography184.108.40.206 Air-Coupled Ultrasound6.7.3 Adjacent Technologies220.127.116.11 Positive Metal Identification Technique18.104.22.168 Dynamic Interferometry 7 Ultrasonic Testing Market, by Type7.1 Introduction7.2 Phased Array7.2.1 Faster Adoption Rate due to Higher Accuracy and Minimal Time Consumption in Inspection and Defect Detection7.3 Time-Of-Flight Diffraction7.3.1 High Precision with Minimal Failure Risk is Driving TOFD Segment7.4 Immersion Testing7.4.1 Capability of Detecting Small Defects is Driving Adoption of Immersion Testing in Industrial and Manufacturing Sectors7.5 Guided Wave Testing7.5.1 High Adoption Rate due to Long Range Inspection and Monitoring Capabilities7.6 Acoustography7.6.1 Ultrasonic Area Inspection Technique is Adopted for Single-Side Inspection for Imaging Process7.7 Others 8 Ultrasonic Testing Market, by Equipment8.1 Introduction8.2 Flaw Detectors8.2.1 Unique Identification Capabilities of Discontinuities Has Increased Adoption Rate of Flaw Detectors in Diverse Verticals8.3 Thickness Gauges8.3.1 Measurement Precision Drives Adoption of Thickness Gauges in Oil & Gas and Power Generation Verticals8.4 Transducers and Probes8.4.1 Critical Inspection Capabilities are Driving Adoption of Transducers and Probes8.5 Industrial Scanners8.5.1 Low Cost and Improved Quality and Precision in Scanning Results Has Increased Adoption of Industrial Scanners8.6 Tube Inspection Systems8.6.1 Large-Scale Adoption in Power Generation Vertical due to High-Precision Detection of Damages Such as Corrosion and Cracks8.7 Bond Testers8.7.1 Bond Testers are Being Highly Adopted in Oil & Gas and Aerospace Verticals8.8 Imaging Systems8.8.1 Increasing Adoption Rate due to Quality Control and Precise Flaw Detection Capabilities8.9 Others 9 Ultrasonic Testing Market, by Service9.1 Introduction9.2 Inspection Services9.2.1 High Adoption Rate due to Better Accuracy and Efficiency, Faster Inspection, and Low Cost9.3 Equipment Rental Services9.3.1 Low Cost and Appropriate Availability as Per Need are Driving Demand for Equipment Rental Services9.4 Calibration Services9.4.1 Increasing Adoption due to Accuracy in Measurement by Reducing Uncertainties in Testing Equipment9.5 Training Services9.5.1 Growing Demand for Ultrasonic Testing Equipment and Services is Driving Need for Training Services in APAC and North American Regions 10 Ultrasonic Testing Market, by Vertical10.1 Introduction10.2 Manufacturing10.2.1 Increase in Adoption Rate due to Need for Monitoring, Inspection, and Quality Control of Materials10.3 Oil & Gas10.3.1 Need for Precision, Reliability, Safety, and Improved Utilization of Materials Led to High Adoption Rate in Oil & Gas Vertical10.3.2 Refining10.3.3 Subsea Pipelines10.3.4 Storage Tanks10.4 Aerospace10.4.1 Need for High Precision, Increased Safety, and Quality Assurance Augment Adoption of Ultrasonic Testing Equipment in Aerospace Vertical10.4.2 Aircraft Engine Part Production to be Key Application Area of Ultrasonic Testing10.4.3 Airplane Maintenance Applications10.5 Government Infrastructure10.5.1 Rising Demand for Infrastructure Development Has Led to Increase in Adoption of Ultrasonic Testing Equipment and Services10.5.2 Military & Defense10.5.3 Railways Industry10.5.4 Bridges and Tunnels10.6 Automotive10.6.1 Ultrasonic Testing Equipment Detect Flaws and Corrosion in Large Automotive Components10.7 Power Generation10.7.1 Rising Demand for Energy Has Led to Increased Use of Ultrasonic Testing Equipment and Services in Power Plants10.7.2 Nuclear Power Drives Growth of Ultrasonic Testing in Power Generation10.7.3 Renewable Energy10.7.4 Fossil Fuel Energy10.8 Marine10.8.1 Ultrasonic Inspection Services are Used in Marine Sector to Ensure Integrity of Ships and Their Components10.9 Others10.9.1 Healthcare10.9.2 Plastics and Polymers 11 Geographic Analysis11.1 Introduction11.2 North America11.3 Europe11.4 Asia-Pacific11.5 Rest of the World 12 Competitive Landscape12.1 Overview12.2 Market Evaluation Framework12.2.1 Product Portfolio12.2.2 Regional Focus12.2.3 Manufacturing Footprint12.2.4 Organic/Inorganic Play12.3 Market Share Analysis, 202012.4 Revenue Analysis of Top 4 Players in Ultrasonic Testing Market12.5 Company Evaluation Quadrant12.5.1 Star12.5.2 Emerging Leader12.5.3 Pervasive12.5.4 Participant12.6 Startup/Sme Evaluation Matrix12.6.1 Progressive Companies12.6.2 Responsive Companies12.6.3 Dynamic Companies12.6.4 Starting Blocks12.7 Company Footprint12.8 Competitive Situation & Trends12.8.1 Product Launches & Developments12.8.2 Deals12.8.3 Others 13 Company Profiles13.1 Key Players13.1.1 Mistras Group13.1.2 Olympus Corporation13.1.3 Baker Hughes (A Subsidiary of GE Company)13.1.4 Intertek13.1.5 Sonatest Ltd13.1.6 Amerapex Corporation13.1.7 Sonotron Ndt13.1.8 Tecscan Systems Inc13.1.9 Ashtead Technology13.1.10 NDT Systems Inc13.1.11 Eddyfi13.1.12 Applied Technical Services Inc13.2 Other Key Players13.2.1 Ndt Global GmbH Ltd & Co.Kg13.2.2 Td Williamson Inc13.2.3 Labquip Ndt Limited13.2.4 Ipromar Pte Limited13.2.5 Fprimec Solutions Inc13.2.6 Cygnus Instruments Ltd13.2.7 Acuren Inspection Inc13.2.8 Dekra13.2.9 Element Materials Technology13.2.10 Fischer Technology Inc13.2.11 Lynx Inspection13.2.12 Carestream13.2.13 Zetec Inc 14 Appendix14.1 Insights of Industry Experts14.2 Discussion Guide For more information about this report visit https://www.researchandmarkets.com/r/f52gyv CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Elang Mahkota Teknologi, better known as Emtek, is betting heavily on the growth of Indonesia’s digital economy, notably streaming service Vidio, which got a boost under last year’s COVID conditions. But it continues to do well with traditional TV, and production activities that can serve both. The mixture has propelled Emtek into the ranks of […]
New York, New York--(Newsfile Corp. - April 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Neptune Wellness Solutions Inc. ("Neptune Wellness") (NASDAQ: NEPT) between July 24, 2019 and February 16, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. ...
The "Labeling and Product Decoration Annual Review 2021" report has been added to ResearchAndMarkets.com's offering.
Downing Strategic Micro-Cap Investment Trust plc (the “Company”) LEI: 213800QMYPUW4POFFX6922 April 2021 Portfolio Update The Directors of the Company note the announcement released by Real Good Food plc (“RGD”) at 11:54am on 22 April 2021 relating to the proposed disposal of Brighter Foods Limited by RGD. Completion of the proposed disposal is expected to result in a total payment to the Company of approximately £5.3m, being a partial redemption of the 10% Loan Notes held by the Company in RGD at their carrying value and the realisation of the redemption premium thereon. The impact of the redemption premium is estimated to result in an increase to the Company’s net asset value (“NAV”) of 1.07p per share. The Directors further note that the Manager has a strong pipeline of qualified new prospects in final due diligence. Enquiries:Shore Capital (Financial Adviser and Broker) Robert Finlay020 7408 4050 Grant WhitehouseDowning LLPCompany Secretary 020 7630 4333
Amit Dave via ReutersThe COVID-19 crisis in India has hit a new low as corrupt scammers are now prowling social media for desperate patients who are willing to pay a premium for hospital bed space and black market drugs. 50 Million People Allowed at Superspreader Festival so Modi Can Secure the Hindu VoteVideo of an undercover sting operation in the Indian city of Rajkot showed a hospital worker selling a hospital bed to a desperate woman whose relative needed critical care. “I won’t take anything less than Rs 9,000,” the worker said, which is about $120. “You will get the bed in 30 minutes.” The family negotiated down to Rs 8,000 and the man called someone inside the hospital who finalized the deal. Within an hour, the sick patient is whisked through a back door of the hospital, skirting the 50 or 60 waiting cars in front. So desperate is the need for coveted hospital space that scenes like this are reportedly playing out across the country as overwhelmed hospitals grapple with a tsunami of patients, critical supply shortages and an obvious lack of vigilance. Indian Hospitals Run Out of Oxygen After Foreign Sales BoomPolice uncovered the deal after following the initial exchange on social media, where many patients are pleading for help. Hospitals have also used social media platforms to plead for supplies like oxygen and drugs. India, which is the world’s largest producer of generic drugs, has also reached a critical shortage of remdesivir and favipiravir, which have both had moderate success in treating COVID-19 patients. Raman Gaikwad, an infectious diseases specialist at Sahyadri Hospital in the western city of Pune, told the Indian Express that remdesivir manufacturers were ordered to cease production in January because of decrease in infections. When the latest wave hit, they were left with severe shortages. “One solution to this crisis was to create a stockpile of antiviral drugs when cases were low,” Gaikwad told the paper. “But that did not happen.”A network of activists, including YouTuber Kusha Kapila, have joined together to try to source and share information on hospital bed availability, pharmacy supplies and food delivery to help people stay away from price gougers on the black market. One of the activists told AFP that there is a new request for help every 30 seconds. An investigation carried out by media outlet India Today trailed a black market ring selling remdesivir for six times the market price. Payments had to be made in cash and the patients were told the drug—which the World Health Organization has said doesn’t even work—would be smuggled out of the hospital. Patients were given injections upon delivery of the cash. On Thursday, India reported a record-breaking 314,000 new COVID-19 infections, the most recorded anywhere in the world since the pandemic began."Covid-19 has hit this country with a ferocity not seen before...but not unexpected either". WARNING - this is a very distressing but necessary report from @yogital, Fred Scott and Sanjay Ganguly on the human catastrophe unfolding in #Delhi. Please watch #CovidIndia #BBCNewsTen pic.twitter.com/A5Pi1nwd0n— Nicola Careem (@NicolaCareem) April 21, 2021 Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
American Airlines Group Inc reported a smaller quarterly loss on Thursday as rising vaccination rates prompted more people to opt for air travel. Demand for air travel is expected to pick up as more people receive vaccines, leading to a drop in COVID-19 infection rates and hospitalizations. American Airlines ended the quarter with about $17.3 billion in available liquidity.